Morgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the company’s latest move into at-home lab ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List Hot List Pro

Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24February 21, 2025 12:23 PM Hims and Hers (HIMS) PT Raised to $21 at BofA SecuritiesFebruary 20, 2025 5:18 AM Hims & Hers Health, Inc. (HIMS) options active on 349K contracts amid sharp rallyFebruary 20, 2025 5:17 AM Form 144 Hims & Hers Health, Inc. Filed by: Chi MichaelFebruary 19, 2025 10:17 AM Hims & Hers Health (HIMS) Acquires At-Home Lab Testing FacilityFebruary 19, 2025 9:01 AM Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for SubscribersFebruary 19, 2025 9:00 AM Hims & Hers Health, Inc. (HIMS) options active on volume of 106K contracts amid wide price movementFebruary 19, 2025 4:54 AM Hims and Hers (HIMS) PT Raised to $68 at Canaccord GenuityFebruary 19, 2025 12:16 AM Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.5 puts with a focus on February 28 weekly putsFebruary 18, 2025 2:47 PM